Herndon Capital Management LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 31.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 313,915 shares of the biopharmaceutical company’s stock after purchasing an additional 74,417 shares during the quarter. Gilead Sciences makes up approximately 3.1% of Herndon Capital Management LLC’s portfolio, making the stock its 3rd largest holding. Herndon Capital Management LLC’s holdings in Gilead Sciences were worth $21,321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Abner Herrman & Brock LLC raised its position in shares of Gilead Sciences by 0.5% in the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 50 shares during the period. Blue Fin Capital Inc. raised its position in shares of Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 55 shares during the period. McKinley Carter Wealth Services Inc. raised its position in shares of Gilead Sciences by 1.3% in the first quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 63 shares during the period. Searle & CO. raised its position in shares of Gilead Sciences by 0.6% in the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock valued at $907,000 after purchasing an additional 80 shares during the period. Finally, Alpha Windward LLC raised its position in shares of Gilead Sciences by 2.4% in the first quarter. Alpha Windward LLC now owns 3,921 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 92 shares during the period. 74.05% of the stock is currently owned by institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.44% on Wednesday, reaching $82.92. 4,170,093 shares of the company traded hands. The company has a market capitalization of $108.29 billion, a P/E ratio of 9.01 and a beta of 1.19. The firm’s 50 day moving average is $74.82 and its 200 day moving average is $69.38. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $84.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the business posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post $8.74 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is presently 22.58%.

A number of equities analysts have recently commented on the stock. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target on the stock. in a research report on Monday. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research report on Wednesday. Berenberg Bank reissued a “buy” rating and issued a $96.00 price target (up previously from $86.00) on shares of Gilead Sciences in a research report on Wednesday. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Thursday, August 31st. Finally, William Blair reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, August 31st. Eleven investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $83.06.

COPYRIGHT VIOLATION NOTICE: “Herndon Capital Management LLC Has $21.32 Million Stake in Gilead Sciences, Inc. (GILD)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/06/herndon-capital-management-llc-has-21-32-million-stake-in-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares in the company, valued at $8,945,723. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 60,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the transaction, the executive vice president now owns 62,715 shares in the company, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 316,666 shares of company stock worth $24,164,584. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.